OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC
OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
Read more on News-Medical-Net
Categories: Metastatic Breast Cancer Tags: Completes, enrollment, FALCON, NSCLC, OXiGENE, Phase, Trial, ZYBRESTAT
Nexavar’s ‘MISSION’ Continues Despite First-Line NSCLC Miss
Nexavar’s ‘MISSION’ Continues Despite First-Line NSCLC Miss
Multikinase inhibitor Nexavar’s (sorafenib) failure in first-line non-small-cell lung cancer came as little surprise to investors of Onyx Pharmaceuticals Inc., who have their eyes trained on much-anticipated Phase IIb data for multiple myeloma drug carfilzomib, which, if positive, could be enough for an FDA filing late this year.
Read more on BioWorld
Categories: Breast Cancer Chemotherapy Tags: Continues, despite, FirstLine, Miss, Mission, Nexavar's, NSCLC
UK NICE recommends Eli Lilly’s ALIMTA as maintenance therapy for nonsquamous NSCLC
UK NICE recommends Eli Lilly’s ALIMTA as maintenance therapy for nonsquamous NSCLC
Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive “Final Appraisal Determination” from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE).
Read more on News-Medical-Net
Categories: Breast Cancer Research Tags: ALIMTA, Lilly's, maintenance, nice, nonsquamous, NSCLC, recommends, Therapy
Novelos Therapeutics Discontinues Current Development Program for NOV-002 in NSCLC
Novelos Therapeutics Discontinues Current Development Program for NOV-002 in NSCLC
NEWTON, Mass.—-Novelos Therapeutics, Inc. , a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer with its lead product, NOV-002, in combination with first-line chemotherapy.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Research Tags: current, Development, Discontinues, NOV002, Novelos, NSCLC, program, Therapeutics'
Novelos Therapeutics’ NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint
Novelos Therapeutics’ NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial …
Read more on News-Medical-Net